Finance

Beta
Lists
GLAXO:NSE
GlaxoSmithKline Pharmaceuticals Ltd
₹2,210.00
-3.75%
(-86.20) 1D
May 29, 3:30:01 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLAXO...
Open
₹2,259.90
High
₹2,267.00
Low
₹2,194.40
Mkt. cap
373.88B
Avg. vol.
84.68K
Volume
304.04K
Dividend
2.58%
Quarterly dividend
₹14.25
Ex-dividend date
May 29, 2026
P/E ratio
36.77
52-wk high
₹3,515.70
52-wk low
₹2,194.40
EPS
₹60.11
Shares outstanding
169.41M
No. of employees
3K
Open
₹2,259.90
High
₹2,267.00
Low
₹2,194.40
Mkt. cap
373.88B
Avg. vol.
84.68K
Volume
304.04K
Dividend
2.58%
Quarterly dividend
₹14.25
Ex-dividend date
May 29, 2026
P/E ratio
36.77
52-wk high
₹3,515.70
52-wk low
₹2,194.40
EPS
₹60.11
Shares outstanding
169.41M
No. of employees
3K
News stories
From sources across the web
Profile
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
About GlaxoSmithKline Pharmaceuticals Ltd
CEO-
Employees3.11K
FoundedNov 13, 1924
Headquarters-
SectorPharmaceutical industry
Websiteindia-pharma.gsk.com
Last report
May 13, 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
- / -
Revenue / Est. (INR)
9.95B / 10.71B
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
8.05B
9.80B
10.41B
9.95B
Cost of goods sold
2.88B
3.56B
3.64B
3.44B
Cost of revenue
2.88B
3.56B
3.64B
3.44B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.53B
1.38B
1.52B
1.65B
Operating expense
2.82B
3.06B
3.26B
3.14B
Total operating expenses
5.69B
6.62B
6.90B
6.58B
Operating income
2.36B
3.18B
3.51B
3.38B
Other non operating income
437.20M
335.70M
321.20M
359.50M
EBT including unusual items
2.79B
3.54B
4.00B
3.73B
EBT excluding unusual items
2.79B
3.51B
3.82B
3.73B
Income tax expense
739.70M
965.10M
1.04B
952.40M
Effective tax rate
26.51%
27.26%
26.08%
25.53%
Other operating expenses
1.14B
1.51B
1.54B
1.36B
Net income
2.05B
2.57B
2.96B
2.78B
Net profit margin
25.46%
26.28%
28.39%
27.92%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-4.20M
-5.10M
-11.90M
-6.10M
Net interest expenses
-4.20M
-5.10M
-11.90M
-6.10M
Depreciation and amortization charges
155.20M
174.30M
203.20M
131.70M
EBITDA
2.45B
3.35B
3.61B
3.54B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer